HOME / JOIN / PROTEOMICS KNOWLEDGE RESOURCE / MAILING LIST / CONTACT US / WECHAT
If you have news that you would like distributed via HUPO's website, newsletter, or social media channels, please email office(at)hupo.org.
A Message from hPOP - Assay Invite
The hPOP project to profile people from around the world has been highly successful in the sample collection. We have collected samples from each of the three regions: Boston (Pilot n = 31 individuals), Taipei (N = 106), Dublin (n = 115), Orlando (n = 84). Plus to increase North American numbers we have collected samples from the Bay area (n = 40).
We are now ready for the analyses. On a google spread sheet we list possible assays. We are looking for volunteers to help carry them out. Feel free to suggest additional assays. Our goal is to get these assays done in the next 2-3 months and then analyze the data and present the results at the next HUPO meeting in Australia. The analyses will take some time because there is lots to do we need to do age correction, BMI, etc. We suggest discussing results/analyses on consortium calls starting in January. Note the Snyder lab signed up for many assays but if there are volunteers to take over some of them that would be fine (we want to make sure that a basic set of analyses is done).
We are also building an interactive database to get the data back to participants.
1. Please sign up for assays on the google spread sheet here.
2. Send any and all comments to us at email@example.com.
Let us know if you would like to participate in any of the consortium calls. This is a very unique project and open access resource-we hope to get a high profile paper out of this.
Norman Anderson passed away November 22, 2018 after a short illness, five months before his 100th birthday. He is known both for visionary Big Science projects (the Molecular Anatomy Program, the Human Protein Index, and Rapid Response to Viral Pandemics) and for a series of widely-used bioanalytical inventions (the zonal ultracentrifuge, the centrifugal fast analyzer, large scale 2-D electrophoresis, and virus purification, which was his creative focus late in life). His career spanned military service in World War II (US Navy), advanced degrees (Duke University), National Laboratories (Oak Ridge and Argonne), commercial biotechnology (Large Scale Biology Corp), and non-profit foundations (Viral Defense Foundation), producing more than 250 publications and 35 patents.
Norman Anderson was raised in a religious family of St. Paul MN, in which his father, brother and both sisters pursued careers in the Norwegian Lutheran church. Joining the Navy during World War II, work in underwater photography, eye movement tracking during instrument flight, and on submarines and blimps, expanded his horizons and allowed him to develop novel equipment and ideas. During the war, he met and rapidly married Mary Lloyd Glidewell, daughter of a prominent lawyer in Reidsville, NC, who provided the genial southern atmosphere that sustained him for their 77 years together. Mary Lloyd encouraged him to follow his scientific interests as a graduate student at Duke, instead of accompanying his Navy friends to Hollywood as a photographer, and after a PhD in cell physiology, Norman accepted a fellowship at Oak Ridge National Laboratory where he remained for 20 years. At Oak Ridge, he developed a plan for the complete fractionation of human cells, and to this end developed the zonal ultracentrifuge (including systems for large scale influenza virus purification still used to produce safe vaccines today), the centrifugal fast analyzer (subsequently commercialized by multiple companies for clinical laboratory testing), and high-pressure liquid chromatography systems.
After a brief interlude at the Medical University of South Carolina, Dr. Anderson moved to Argonne National Laboratory near Chicago, where, together with his son Leigh Anderson, he pioneered the use of large-scale 2-D electrophoresis to catalog the human proteins. The potential of this technology led them to start Large Scale Biology Corp. (LSBC), leading to the complete automation of 2-D electrophoresis and the creation of protein databases, as well as development of a large-scale centrifugal oligonucleotide synthesizer (PCOS). After merging with a California-based protein expression company, LSBC completed a highly successfully IPO in 2000.
Over the past 15 years Dr. Anderson focused his attention on the problem of detecting newly emerging viruses and rapidly creating vaccines to prevent their spread as epidemics. His vision of a Manhattan Project-style approach to this existential challenge to civilization highlighted the differences between modern mechanisms of grant-based scientific research and the scale, commitment and speed possible in the context of a World War.
Dr. Anderson received a number of awards including the Distinguished Clinical Chemist Award from the International Federation for Clinical Chemistry (1990); the 1983 Pittsburgh Analytical Chemistry Award (1983) for work in high resolution two-dimensional electrophoresis (shared with N. Leigh Anderson); an Docteur Honoris Causa, University of Nancy, France; the John Scott Medal and Award for the invention of the zonal ultracentrifuge (1972); the Atomic Energy Commission Citation and Gold Medal for the invention and development of the K-II vaccine-purification ultracentrifuge (1972); the Preis für Biochemische Analytik, awarded by the Deutsche Gesellschaft für Klinische Chemie for the invention of the centrifugal fast analyzer (1972); and a U.S. Navy Special Citation for outstanding work as a combat photographic officer in the submarine service in the Pacific during WWII (1946).
Norman Anderson is survived by his son (Leigh Anderson), with whom he collaborated in proteomics research for more than 40 years, Leigh’s wife Constance Seniff, and his daughter (Beth Anderson, successively a ballerina, rock musician, scientific instrument builder and science animator), and her husband Douglas Huff. Mary Lloyd died six months before him, which was a great blow. Norman is fondly remembered by a host of co-workers, students and neighbors in whom his perpetual enthusiasm excited a profound interest in science.
Following an international search, the Human Proteome Organization (HUPO; www.hupo.org) has recently selected cancer researcher Mark Baker from Macquarie University, Australia as the incoming Chair of the Human Proteome Project. Effective January 2019, Mark will succeed pioneering physician-scientist Gilbert (Gil) Omenn from the University of Michigan, USA who led this emerging global collaborative project since launch in 2010.
The Human Proteome Project brings together an impressive array of research teams from around the globe, focused on achieving highly-confident detection and identification of all the expressed proteins that are predicted to be coded by the human genome. The Human Proteome Project then aims to characterize the proteome’s sequence, splice and chemical modifications that alter locations, function and interaction. The Human Proteome Project is cooperating with the broader scientific community to annotate biological, chemical, cellular and disease aspects of the human proteome using rapidly-evolving technologies.
One outcome will be a comprehensive “map” of protein pathways and networks that will demonstrate the indispensable role our proteomes play in precision medicine - because we know it is impossible to predict these dynamic, structural and functional details of biology just by sequencing our genomes.
Sustained progress through the Human Proteome Project will noticeably enhance our understanding of human biology at the molecular level, lay solid foundations for monitoring health and the development of new preventive, diagnostic, prognostic and therapeutic interventions in disease, and increase our biological understanding of what it means to be human.
Contacts for Comment:
Professor Mike Snyder - HUPO President, Stanford University, USA firstname.lastname@example.org
Ms Chelsea Prangnell - Manager, Human Proteome Organization email@example.com
The Nominations and Elections Committee of the Human Proteome Organization presents the official slate of candidates for the 2018 HUPO Council election. HUPO would like to thank all candidates standing for Council election for a three-year term beginning in January 2019 (2019-2021). The election period for HUPO Council is September 5 - September 30, 2018.
In September, all active HUPO members will receive an email containing online voting instructions with a secure election ID code. Electors will simply click on the link provided to cast their anonymous votes.
The slate of candidates is now available here. We encourage you to review the slate of candidates prior to the election opening date on September 5, 2018.
Chair, HUPO Nominations and Elections Committee
Deadline January 14, 2018: Institut Pasteur has launched an international call for junior candidates wishing to establish new independent research groups in the cutting edge interdisciplinary environment of its campus in Paris, France. This year the call will be focused on the topics associated with the INstitut Convergence entitled “Emergence of Pathologies Through Individuals and populatiONs” (INCEPTION program). Read on here.
HUPOST: Can you tell us what this prize, which is referred to as the Dutch Nobel Prize, means for you, and for the field?
Heck: The Spinoza prize is the most prestigious Dutch science award, and is given annually to three to four researches, selected from all disciplines of science.
It is of course an enormous honour to be awarded this prize, and while it’s known as the Dutch Nobel Prize, it evidently does not compare to the real Nobel. Nevertheless, it comes with a 2.5 million euro budget, to be spend freely for research, so it is a very strong driver for creativity and innovation.
Although a personal prize, I think this award is also an award for my group and the field, because the prize is an implicit recognition for the importance and impact of analytical chemistry, biomolecular mass spectrometry and proteomics.
HUPOST: You have your own Wikipedia page, and a list of prestigious awards to your name. What would be your advice to young researchers who want to make a difference?
Heck: If you want to make a difference, evidently you should keep up with the literature, so you know what lives in the field, but that knowledge should not stop you from doing the unexpected and you should always look for unexpected findings. In my view, these are the key to innovation and succes. And I try to encourage everyone not to be a follower; try doing something different than the other labs in your field. When you have a keen eye for the unexpected, and do original work, then you will be able to contribute unique findings and can make a difference. And find the right environment, as good mentors are way more important than a good lab-infrastructure.
HUPOST: When a researcher pursues something different, the research can also fail. Do you have any tips on how to deal with such setbacks?
Heck: We should not fear failure. In fact, most scientific experiments end in failure. There’s no satisfaction to be had from planning an experiment for which the outcome is already known. And never forget: after you encounter a few failures, the next success will taste so much sweeter!
HUPOST: If you were a starting scientist today, what topic would you choose?
Heck: My main driver is very broad: understanding how life works at the molecular level. Of course, ‘life’ is very diverse, and there’s much to study. But right now, I would love to look more into how the brain works at the molecular level. This is an area we still understand so little about.
In general, I strongly believe that everybody needs to find something that strongly attracts their interest, as it is very important in science to work on a topic you really care about.
HUPOST: Your lab has also produced very nice short movies to introduce science to the general public; how important is this outreach?
Heck: I think it is very important and exciting to outreach to the general public. But I have also learned that you need to have a strategy for these movies, so that they hit their mark. Importantly, it is also very much fun to make such movies. Overall, I believe that if you study proteins, and are excited about proteins, as I am, that you should also spread this excitement! And because the general public will not read our papers in Nature and Science, such movies are a great way to bring our research to a broader audience. It is particularly rewarding to see that some of our movies are featured in the Washington Post, but these are used in classrooms as well. If you make a movie, try to make them as multi-purpose as possible.
HUPOST: While on the subject of classrooms, do you believe that knowledge about proteomics should move into classrooms?
Heck: Yes, of course, although I would prefer a more overall view: we should be teaching more insight into life at the molecular level in the classrooms, and this should be based on knowledge of the entire cast of macromolecules (DNA, RNA, proteins) that feature in this grand spectacle we call live.
I also think that the progress of scientific knowledge in the life sciences are taking too long to reach the classrooms, and that is a pity. All the more so because the knowledge is so interesting and inspiring. A great example is the gene transcription machinery, which is not only a fundamental process in all life, but it also combines proteins, DNA, and RNA in a fascinating molecular machine.
HUPOST: Which of your contributions to the field gave you the most satisfaction?
Heck: That’s a difficult question. It’s like being asked to pick the favourite child amongst your children. But I really enjoy technology development. This because there is great satisfaction in receiving mails from other researchers that write to let you know that your technology has helped them do their research. Science is all about sharing after all, and when people pick up technologies that you’ve developed, and it works for them, that is extremely motivating.
In addition, new technologies often lead to breakthrough findings in biology. For instance, the EThcD technology we developed has led to the discovery of widespread proteasomally spliced HLA peptides, which shook up the field of immunology. So I really like the ability of technological breakthroughs to lead to a new understanding of biology, which is, after all, the goal!
Paper reference: http://science.sciencemag.org/content/354/6310/354
The MS-Pillar of the Human Proteome Project invites all HUPO members to participate in the Phosphopeptide challenge. The MS Resource Pillar has partnered with SynPeptide Co. Ltd in Shanghai (www.synpeptide.com) to develop a complex set of human phosphopeptides (Ser, Thr or Tyr) singly and multiply phosphorylated) and their unphosphorylated counterparts that can be used for method development and verification for phosphopeptide enrichment, sequence analysis by mass spectrometry and bioinformatic evaluation. The first stage of this initiative is for interested members of the HUPO community to obtain a set of the peptides and apply their own methods and bioinformatic analysis to fully characterize the peptides as a neat mixture and in a tryptic digest background. As a result of this collaborative endeavor, multiple purification schemes, analytical protocols and data processing strategies will be evaluated, making it possible to determine the approach(es) that provide the highest coverage of phosphopeptides in the mixture.
By partnering with SynPeptide the peptide sets are being provided free-of-charge to all HUPO members, with the understanding that the analytical and data processing methods and results will be returned to the MS Resource Pillar committee so they can be collated and reported at the HUPO 2018 meeting. Free aliquots of the peptide mixtures can be obtained at the HUPO2017 Congress in Dublin from Peter Hoo from the SynPeptide stand. MS-Pillar Chair Prof. Sue Weintraub will make a short presentation on Monday September 18 at 16:30.
The Human Proteome Organization (HUPO) and Prof Steve Pennington, UCD, chair of the organizing committee of HUPO2017 (the 16th HUPO World Congress) in collaboration with the National Cancer Institute’s (NCI) International Cancer Proteogenome Consortium (ICPC) announce that they will host a HUPO2017 Global Leadership Gala Dinner on Saturday 16th September. The event is catalyzed in part, by the Cancer Moonshot initiative. The organizers are delighted that the 47th Vice President of the United States of America Joseph R. Biden Jr. will deliver a keynote address at the dinner on the theme of “International Cooperation in the Fight Against Cancer.”
The evening dinner event being held in the Royal College of Physicians in Dublin will bring together the world’s leading proteomic and proteogenomic researchers including those working on cancer research in the company of government, academia and industry leaders. The event will focus on both raising awareness of HUPO and its activities, and advances in proteomics and their impact on human health, as well as the ICPC which currently comprises 11 countries and seeks to encourage more institutions to join this global partnership.
“Every day, every minute matters to patients and we must bring that sense of urgency to our cancer research and care systems.”
Catalyzed by the efforts of the Cancer Moonshot launched in 2016 by the 47th U.S. Vice President Joseph R. Biden Jr., this year’s HUPO Annual World Congress (HUPO2017) will encourage further collaborations among countries and institutions that represent the great diversity of people and of cancers. Echoing the call of the Cancer Moonshot to accelerate progress against cancer around the world, ICPC (International Cancer Proteogenome Consortium) has currently signed Memorandums of Understanding with 11 countries, encompassing multiple institutions that have pledged to publicly share their proteogenomic data (hosted by the U.S. National Cancer Institute) to accelerate the understanding of common and rare cancers around the world. ICPC teams use an integrated proteogenomic approach, as previously shown by the U.S. National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) to provide more information and insight into cancer’s development and growth, with the aim of leading to better patient care.
For further information and details, contact:
HUPO2017: Professor Steve Pennington: firstname.lastname@example.org
HUPO: Chelsea Prangnell: email@example.com
U.S. National Cancer Institute: firstname.lastname@example.org
Dear HUPO colleagues,
HUPO takes knowledge transfer seriously in the current increasingly competitive communication and funding circumstances. The HUPO Marketing Committee is assembling a series of exciting scientific/clinical/technological Success Stories that either proteomics and/or HUPO have delivered.
The taskforce (Mark Baker (chair), Christoph Borchers, Michelle Hill, Pierre Legrain, Charles Pineau and Lennart Martens) asks you to illustrate/describe the Success Story. In addition, the committee will seek comments about impact from eminent researchers and industry alike. These Success Stories will be assembled annually into a constantly growing portfolio, and when each story is complete it will be made available in high-quality print as pdfs, through Facebook, LinkedIn, Twitter, on our integrated HUPO/HPP website and through our HUPO and HPP newsletters.
The committee will accept Success Story suggestions at any time, preferably through the following web-based nomination form:
Scientists, clinicians and industry are all encouraged to submit.
Please feel free to communicate any proteomics/HUPO breakthrough Success Story.
Mark S. Baker
Past President | Human Proteome Organization
The Human Proteome Organization is a 501(c)(3) tax exempt non-profit organization registered in the state of New Mexico. | © 2021 HUPO